Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

Mosaburo Kainuma, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Junya Shimono, Shinji Shimoda, Jun Hayashi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Aim: To analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) in older Japanese patients (65 years or older) infected with hepatitis C virus (HCV). Methods: This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk. Results: At 24 wk after the end of combination therapy, the overall sustained virological response (SVR) for genotypes 1 and 2 were 40.7% and 79.6%, respectively. The SVR rate decreased significantly with age in each genotype, and was markedly reduced in genotype 1 (P < 0.001). Moreover, the SVR was significantly higher in patients with genotype 1 who were less than 65 years (47.3% of 685) than in those 65 years or older (22.9% of 253) (P < 0.001) and was higher in patients with genotype 2 who were less than 65 years (82.9% of 252) than in those 65 years or older (65.6% of 61) (P = 0.004). When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV, the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older (P <0.001). Adverse effects resulted in treatment discontinuation more often in patients with genotype 1 (14.4%) than in patients with genotype 2 (7.3%), especially by patients 65 years or older (24.1%). Conclusion: PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage.

Original languageEnglish
Pages (from-to)4400-4409
Number of pages10
JournalWorld Journal of Gastroenterology
Volume16
Issue number35
DOIs
Publication statusPublished - Sep 21 2010

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Genotype
Hepacivirus
Therapeutics
Multicenter Studies
Safety

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Kainuma, M., Furusyo, N., Kajiwara, E., Takahashi, K., Nomura, H., Tanabe, Y., ... Hayashi, J. (2010). Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World Journal of Gastroenterology, 16(35), 4400-4409. https://doi.org/10.3748/wjg.v16.i35.4400

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. / Kainuma, Mosaburo; Furusyo, Norihiro; Kajiwara, Eiji; Takahashi, Kazuhiro; Nomura, Hideyuki; Tanabe, Yuichi; Satoh, Takeaki; Maruyama, Toshihiro; Nakamuta, Makoto; Kotoh, Kazuhiro; Azuma, Koichi; Shimono, Junya; Shimoda, Shinji; Hayashi, Jun.

In: World Journal of Gastroenterology, Vol. 16, No. 35, 21.09.2010, p. 4400-4409.

Research output: Contribution to journalArticle

Kainuma, M, Furusyo, N, Kajiwara, E, Takahashi, K, Nomura, H, Tanabe, Y, Satoh, T, Maruyama, T, Nakamuta, M, Kotoh, K, Azuma, K, Shimono, J, Shimoda, S & Hayashi, J 2010, 'Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C', World Journal of Gastroenterology, vol. 16, no. 35, pp. 4400-4409. https://doi.org/10.3748/wjg.v16.i35.4400
Kainuma, Mosaburo ; Furusyo, Norihiro ; Kajiwara, Eiji ; Takahashi, Kazuhiro ; Nomura, Hideyuki ; Tanabe, Yuichi ; Satoh, Takeaki ; Maruyama, Toshihiro ; Nakamuta, Makoto ; Kotoh, Kazuhiro ; Azuma, Koichi ; Shimono, Junya ; Shimoda, Shinji ; Hayashi, Jun. / Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. In: World Journal of Gastroenterology. 2010 ; Vol. 16, No. 35. pp. 4400-4409.
@article{e93750aca0bf4e279b2dda8f9305634e,
title = "Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C",
abstract = "Aim: To analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) in older Japanese patients (65 years or older) infected with hepatitis C virus (HCV). Methods: This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk. Results: At 24 wk after the end of combination therapy, the overall sustained virological response (SVR) for genotypes 1 and 2 were 40.7{\%} and 79.6{\%}, respectively. The SVR rate decreased significantly with age in each genotype, and was markedly reduced in genotype 1 (P < 0.001). Moreover, the SVR was significantly higher in patients with genotype 1 who were less than 65 years (47.3{\%} of 685) than in those 65 years or older (22.9{\%} of 253) (P < 0.001) and was higher in patients with genotype 2 who were less than 65 years (82.9{\%} of 252) than in those 65 years or older (65.6{\%} of 61) (P = 0.004). When patients received a dosage at least 80{\%} or more of the target dosage of PEG-IFN α-2b and 60{\%} or more of the target dosage of RBV, the SVR rate significantly increased to 66.5{\%} in patients less than 65 years and to 45.2{\%} in those 65 years or older (P <0.001). Adverse effects resulted in treatment discontinuation more often in patients with genotype 1 (14.4{\%}) than in patients with genotype 2 (7.3{\%}), especially by patients 65 years or older (24.1{\%}). Conclusion: PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage.",
author = "Mosaburo Kainuma and Norihiro Furusyo and Eiji Kajiwara and Kazuhiro Takahashi and Hideyuki Nomura and Yuichi Tanabe and Takeaki Satoh and Toshihiro Maruyama and Makoto Nakamuta and Kazuhiro Kotoh and Koichi Azuma and Junya Shimono and Shinji Shimoda and Jun Hayashi",
year = "2010",
month = "9",
day = "21",
doi = "10.3748/wjg.v16.i35.4400",
language = "English",
volume = "16",
pages = "4400--4409",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "35",

}

TY - JOUR

T1 - Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

AU - Kainuma, Mosaburo

AU - Furusyo, Norihiro

AU - Kajiwara, Eiji

AU - Takahashi, Kazuhiro

AU - Nomura, Hideyuki

AU - Tanabe, Yuichi

AU - Satoh, Takeaki

AU - Maruyama, Toshihiro

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Azuma, Koichi

AU - Shimono, Junya

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2010/9/21

Y1 - 2010/9/21

N2 - Aim: To analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) in older Japanese patients (65 years or older) infected with hepatitis C virus (HCV). Methods: This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk. Results: At 24 wk after the end of combination therapy, the overall sustained virological response (SVR) for genotypes 1 and 2 were 40.7% and 79.6%, respectively. The SVR rate decreased significantly with age in each genotype, and was markedly reduced in genotype 1 (P < 0.001). Moreover, the SVR was significantly higher in patients with genotype 1 who were less than 65 years (47.3% of 685) than in those 65 years or older (22.9% of 253) (P < 0.001) and was higher in patients with genotype 2 who were less than 65 years (82.9% of 252) than in those 65 years or older (65.6% of 61) (P = 0.004). When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV, the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older (P <0.001). Adverse effects resulted in treatment discontinuation more often in patients with genotype 1 (14.4%) than in patients with genotype 2 (7.3%), especially by patients 65 years or older (24.1%). Conclusion: PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage.

AB - Aim: To analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) in older Japanese patients (65 years or older) infected with hepatitis C virus (HCV). Methods: This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk. Results: At 24 wk after the end of combination therapy, the overall sustained virological response (SVR) for genotypes 1 and 2 were 40.7% and 79.6%, respectively. The SVR rate decreased significantly with age in each genotype, and was markedly reduced in genotype 1 (P < 0.001). Moreover, the SVR was significantly higher in patients with genotype 1 who were less than 65 years (47.3% of 685) than in those 65 years or older (22.9% of 253) (P < 0.001) and was higher in patients with genotype 2 who were less than 65 years (82.9% of 252) than in those 65 years or older (65.6% of 61) (P = 0.004). When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV, the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older (P <0.001). Adverse effects resulted in treatment discontinuation more often in patients with genotype 1 (14.4%) than in patients with genotype 2 (7.3%), especially by patients 65 years or older (24.1%). Conclusion: PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage.

UR - http://www.scopus.com/inward/record.url?scp=77957585975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957585975&partnerID=8YFLogxK

U2 - 10.3748/wjg.v16.i35.4400

DO - 10.3748/wjg.v16.i35.4400

M3 - Article

C2 - 20845506

AN - SCOPUS:77957585975

VL - 16

SP - 4400

EP - 4409

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 35

ER -